Precision NanoSystems Inc.

Vancouver,  BC 
Canada
http://www.precisionnanosystems.com


Create Transformative Medicines. Translate Biology Insights.

PNI is a global leader ushering in the next wave of genetic medicines in infectious diseases, cancer, and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate biology insights into non-viral genetic medicines. 

Join Us for Our Presentation: 

Stop by our booth #458 to live chat with one of our scientific specialists, schedule one on one meetings, download our resources, and watch our videos. 

Check Out Our Digital Poster Presentations:
  • #473 - Production of Superior RNA CAR T Cells Using a Novel Lipid Nanoparticle Delivery Platform - presented by Reka Geczy
  • #477 - Accelerating the Production of Self-Amplifying mRNA (saRNA) Vaccines Using Microfluidics - presented by Sri Abbina
  • #479 - Lipid Nanoparticle Library for Non-Viral Delivery of mRNA and saRNA Towards Vaccine and Cell & Gene Therapy Applications - presented by Nikita Jain


 Videos

Precision NanoSystems
GenVoy-ILM T-Cell Kit for mRNA
NanoAssemblr® Platform

 Press Releases

  • Vancouver, BC, Apr 20, 2021 - Precision NanoSystems (PNI), a global leader in innovative solutions for genetic medicine development, today launched the GenVoy-ILM™ T Cell Kit for mRNA to enable lipid nanoparticle (LNP)-based ex vivo gene transfer. Scientists can now use mRNA-LNP to efficiently and reproducibly generate high yields of engineered primary human T cells using a simple workflow.

    The GenVoy-ILM T Cell Kit for mRNA uses LNP designed to exploit endogenous uptake pathways to efficiently deliver mRNA into activated human primary T cells to mediate titratable, uniform protein expression levels with high cell viability. The mRNA-LNP are also compatible with established T cell culture media allowing rapid integration into existing workflows. The combination of non-disruptive mRNA delivery technology and seamless integration with cell culture protocols eliminates cell recovery times post-treatment to accelerate the production of T cell therapies.

      

     “The COVID-19 mRNA-LNP vaccines have demonstrated the power of lipid nanoparticle technology for the rapid development of highly effective genetic medicines,” said Dr. James Taylor, CEO & cofounder of PNI. “PNI believes that LNP technology can also accelerate the development of transformative cell therapies and we are thrilled to launch a LNP reagent kit specifically designed for the efficient delivery of mRNA into T cells using PNI’s proprietary GenVoy-ILM delivery platform.”

    Dr. Angelo Cardoso, Director of the Laboratory for Cellular Medicine at the Beckman Research Institute at City of Hope, also expressed excitement about PNI’s launch of GenVoy-ILM T Cell Kit for mRNA, “LNP designed for defined cell types open new opportunities for the manufacture of gene-edited cell therapies and, hopefully in the future, in vivo gene targeting.”

    Learn more about the GenVoy-ILM T Cell Kit for mRNA by registering for our upcoming webinars on May 6th and May 11th. And join us at the American Society of Gene & Cell Therapy Annual Meeting for a PNI sponsored symposium “Accelerating Genetic Medicine Development with Lipid Nanoparticles" at 2-3:30 PM ET on May 13th, 2021.

    Learn more about those events at https://www.precisionnanosystems.com/resources-and-community/learningpaths/events

    Learn more about Precision NanoSystems and the GenVoy-ILM T Cell Kit for mRNA at https://www.precisionnanosystems.com/platform-technologies/genvoy-platform/t-cell-kit-for-mrna

    About Precision NanoSystems Inc. (PNI)

    PNI is a global leader ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world’s leading drug researchers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

  • Investment will bring Canada’s first centre of manufacturing excellence of nanomedicine-based RNA vaccines, gene therapies and cell therapies.

    -At project completion early in 2023, the approximately 40,000 square foot leased bio-manufacturing facility will have multiple GMP suites with manufacturing lines for the end-to-end manufacturing of genetic medicines.

    -The contribution is being made through the Government of Canada’s Strategic Innovation Fund , a program designed to attract and support high-quality business investments across all sectors of the economy. 

    Vancouver BC. Precision NanoSystems, Inc. (PNI), a global leader in technologies and solutions for development of genetic medicines, announced today that it has received a contribution of CAD $25.1 million through the Strategic Innovation Fund (SIF). This contribution will support a CAD $50.2-million project to establish a biomanufacturing centre in Vancouver dedicated to the production of ribonucleic acid (RNA) lipid nanoparticle vaccines and genetic medicines. The centre will support the Government of Canada’s national biomanufacturing strategy to expand production capacity of critical medicines for the prevention and treatment of diseases such as COVID-19.

    “Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian companies advance made-in-Canada vaccines and therapies, while securing domestic manufacturing options for international vaccine candidates. This is all part of our government’s commitment to protect the health and safety of all Canadians today, and in the future”, said the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry.

    PNI supports the development of genetic medicines by providing products and services to its clients worldwide who are creating new treatments for infectious diseases, rare diseases, cancer and other areas of unmet need. This project will help PNI establish a Biomanufacturing Centre that will expand Canada’s epidemic and pandemic preparedness capacity and will enable PNI to expand its development and manufacturing services to support the clinical development and supply of new medicines. 

    “PNI’s centre of manufacturing excellence of nanomedicine will be a state-of-the-art facility for the development and manufacture of genetic therapeutics and vaccines,” James Taylor, CEO, Precision NanoSystems stated. “The centre will continue Canada’s leadership in the creation of innovative solutions for the development and production of new medicines for the benefit of patients in Canada and beyond.  This support from the Government of Canada helps PNI to further achieve our mission of accelerating the creation of transformative medicines that significantly impact human well-being.”

    About Precision NanoSystems Inc. (PNI)

    PNI is a global leader ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

  • -PNI will use the investment to advance a cost-effective Made-in-Canada COVID-19 vaccine

    -PNI offers expertise in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine manufacturing

    -PNI will contribute to Canada’s ability to secure an effective COVID-19 vaccine and build technologies towards enabling rapid response against future pandemics

     

    Vancouver BC. Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine. PNI will use the investment to advance a best-in-class COVID-19 mRNA vaccine candidate to clinical trials.

    PNI provides over 250 industry and academic partners with solutions for the development of vaccines, gene therapies, and cell therapies, in the areas of infectious diseases, oncology and rare diseases. With this investment from the Government of Canada, PNI’s Chief Scientific Officer, Dr. Andrew Geall, and his team will use their state-of-the-art technology platforms and expertise in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine manufacturing to develop a cost-effective COVID-19 vaccine.

    As part of Canada’s efforts to combat COVID-19, the Strategic Innovation Fund is working diligently to support projects led by the private sector for COVID-19 related vaccine and therapy clinical trials to advance Canada's medical countermeasures in the fight against COVID-19. “An effective vaccine will be critical as we work to contain the COVID-19 virus and prevent future infections. Today’s contribution will support PNI to advance the development of a mRNA vaccine candidate through pre-clinical studies and clinical trials to help protect Canadians,” stated the Honorable Navdeep Bains, Minister of Innovation, Science and Industry.

    Bringing together its proprietary technology platforms, key partnerships and unparalleled expertise in nanomedicines, PNI is excited to be leading the development of a Made-in-Canada COVID vaccine. James Taylor, CEO and co-founder of PNI said “Since its inception PNI has executed on its mission to accelerate the creation of transformative medicines.  It is an honor to be supported by the Canadian government in this global fight against COVID-19 and to further build capabilities for rapid response against COVID-19 and future pandemics”

     

    About Precision NanoSystems Inc. (PNI)

    PNI is a global leader ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world’s leading drug researchers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.


 Products

  • The NanoAssemblr® Ignite™
    As part of the NanoAssemblr® Platform, the NanoAssemblr® Ignite™ enables the rapid and controlled manufacture of nanomedicines. Conceived for the development of transformative medicines at the bench scale....

  • Advance Novel Genetic Medicine Formulations

    Genetic medicines have a wide design space that requires optimization to select a lead candidate. The Ignite is ideal for fine-tuning process parameters and compositions for further scale up to the clinic.

    Download our brochure here. 



     

  • The NanoAssemblr® Spark™
    The NanoAssemblr Spark enables the acceleration of nanomedicine development through the rapid and easy production of ultra-low nanoparticle volumes for discovery....

  • Explore innovative nanomedicine formulations and create revolutionary medicines with the Spark’s scalable and robust microfluidic system, with minimal consumption of starting materials. The Spark system is designed to be seamlessly integrated with in vitro screening workflows: create on-demand formulations in a sterile biosafety hood and apply them directly to cells in culture. The Spark instrument streamlines the screening of various formulation parameters for novel excipients and nanoparticle cargoes. It may also be used in conjunction with PNI’s line of Spark Transfection Kits to formulate particles for in vitro nucleic acid delivery.

    Download our brochure here.

  • The NanoAssemblr® Blaze™
    The NanoAssemblr® Blaze allows rapid scaling of nanoparticle formulations for late pre-clinical development....

  • Power to Scale.

    The system can manufacture between 10 mL and 10 L of formulation which allows researchers to use the Blaze for preclinical toxicology testing, and for early Chemistry, Manufacturing and Controls (CMC) studies. 

    Download our brochure here.

  • The NanoAssemblr® GMP System
    Complete the journey by transferring your manufacturing processes from PNI’s preclinical systems to the NanoAssemblr GMP System....

  • The GMP System is the only commercially available, turn-key system for the production of clinical grade LNP allowing you to scale up production in your facility under cGMP guidelines.

    For more information click here

  • GenVoy-ILM™
    Power to Explore.

    GenVoy-ILM, an off-the-shelf Research Use Only lipid nanoparticle reagent, lowers the barriers to developing genetic medicines

    ...

  • Lipid nanoparticles (LNP) are the most clinically advanced non-viral delivery technology and have been designed specifically to overcome the RNA delivery challenge. Onpattro® (patisiran) is a siRNA-LNP therapeutic approved to treat hereditary transthyretin amyloidosis. GenVoy-ILM is a pre-optimized lipid mixture designed to encapsulate RNA – mRNA, gRNA, siRNA, miRNA, tRNA – in LNP. GenVoy-ILM is an effective tool to develop RNA medicines and can be used at various stages of drug development from discovery to late preclinical. GenVoy-ILM is easy-to-use and effectively delivers RNA to cells with high efficiency and low toxicity.

    Please download our brochure here. 

  • GenVoy-ILM™ T Cell Kit for mRNA
    Rethink T Cell Gene Delivery.

    Lipid Nanoparticle (LNP) based technology enables researchers to establish a clinically relevant, scalable method for ex vivo gene delivery....

  • The GenVoy-ILM T Cell Kit for mRNA is an LNP reagent mix optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr® Spark™ instrument and cartridges. It can be used at various stages of cell therapy research and development from discovery to preclinical.